Health ❯Clinical Trials

Drug Development

Adverse Effects Research Disease Prevention Hormones Cell Signaling Weight Loss Strategies Biotechnology Age-related Diseases Medical Innovations Digestive Health

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

The phase 1 data reveal sustained weight reduction with tolerable gastrointestinal effects ahead of planned 2026 phase 3 trials.

Silencing Enzyme Gene Boosts NK Cell Cancer-Fighting Power

Cancer drug pair extends mouse lifespan by 30% as researchers plan human trials

SYNT-101 Shows Promise in Early Human Trials as a Non-Invasive Obesity Treatment

Adam Male Contraceptive Implant Shows Two-Year Efficacy in Phase 1 Trials

Sanofi Secures $1.9 Billion Deal for Dren Bio’s Innovative Autoimmune Therapy

AstraZeneca Acquires Belgian Biotech EsoBiotec in $1 Billion Deal